Patents by Inventor Jacqueline Perrigoue

Jacqueline Perrigoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA
    Publication number: 20240010718
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Application
    Filed: June 1, 2023
    Publication date: January 11, 2024
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
  • Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
    Patent number: 11780911
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: October 10, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
  • Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
    Publication number: 20220372129
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF? inhibitor, such as an anti-TNF? antibody (e.g., golimumab).
    Type: Application
    Filed: May 19, 2022
    Publication date: November 24, 2022
    Inventors: Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue, Marion Vetter
  • Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
    Publication number: 20210363234
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Application
    Filed: May 20, 2021
    Publication date: November 25, 2021
    Inventors: Mathew Germinaro, Christopher O'Brien, Jacqueline Perrigoue, Marion Vetter
  • Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
    Publication number: 20200369761
    Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
    Type: Application
    Filed: May 21, 2020
    Publication date: November 26, 2020
    Inventors: Mathew Germinaro, Christopher O'Brien, Jacqueline Perrigoue